TP53 and permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome: K-ras, p53, serum CA19-9 and CEA have been the most widely used biomarkers for PaCa diagnosis [3, 4], but these biomarkers often lead to incorrect diagnosis for PaCa and other non-cancer pancreatic diseases (e.g., chronic pancreatitis) because of their unreliable sensitivity (SEN) and improper specificity (SPE) [4, 5], so that diagnosis of PaCa remains a major clinical challenge.